Correlation Engine 2.0
Clear Search sequence regions

  • antibodies (1)
  • humans (1)
  • immunotoxins (9)
  • toxin (4)
  • Sizes of these terms reflect their relevance to your search.

    The development of recombinant immunotoxins (RITs) as a novel therapeutic strategy has made a revolution in the treatment of cancer. RITs result from the fusion of antibodies to toxin proteins for targeting and eliminating cancerous cells by inhibiting protein synthesis. Despite indisputable outcomes of RITs regarding inhibition of multiple cancer types, high immunogenicity has been known as the main obstacle in the clinical use of RITs. Various strategies have been proposed to overcome these limitations, including immunosuppressive therapy, humanization of the antibody fragment moiety, generation of immunotoxins originated from endogenous human cytotoxic enzymes, and modification of the toxin moiety to escape the immune system. This paper is devoted to review recent advances in the design of immunotoxins with lower immunogenicity. Copyright© Bentham Science Publishers; For any queries, please email at


    Maryam Dashtiahangar, Leila Rahbarnia, Safar Farajnia, Arash Salmaninejad, Arezoo Gowhari Shabgah, Samaneh Ghasemali. Anti-cancer Immunotoxins, Challenges, and Approaches. Current pharmaceutical design. 2021;27(7):932-941

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33023437

    View Full Text